Neuroscience Surge Adds Diversification But Doesn't Change Immunology-Centric Story

What happened

AbbVie's Q1 results showed neuroscience sales jumping 26%, driven by Vraylar, migraine drugs, and Botox for therapeutic use. While this demonstrates successful pipeline diversification beyond immunology, the neuroscience segment remains a smaller contributor compared to the Skyrizi/Rinvoq platform, which together constitute ~42% of 2025 revenue and are the primary drivers of the 2026 $34.5B immunology guidance. The headline strength in neuroscience is positive but does not alleviate the core dependence on immunology share capture and the conditional Rinvoq exclusivity runway to 2037. Management's emphasis on neuroscience growth may buffer some aesthetics weakness, but it does not shift the fundamental thesis that AbbVie's valuation hinges on sustained demand-led execution in immunology.

Implication

Investors should view the neuroscience beat as a confirmation of pipeline optionality, but the core investment case still depends on Skyrizi and Rinvoq delivering on the 2026 immunology framework of $34.5B. Aesthetic segment challenges persist, and the IRA overhang on Botox remains. The wait stance is unchanged until there is clear evidence that immunology revenue is driven by sustainable volume growth, not timing or one-time factors. The next 6 months should focus on quarterly immunology trends and Rinvoq exclusivity milestones.

Thesis delta

The neuroscience strength adds a modest positive signal but does not alter the central thesis that AbbVie's valuation is driven by immunology execution and Rinvoq duration. The wait rating persists, as the market already prices in successful Humira transition; any further upside requires proof that immunology growth is demand-led and policy risks are contained.